You have 0 items in your cart
The amylin field is becoming increasingly crowded.
Alongside cagrilintide, petrelintide and eloralintide, another experimental peptide has now produced notable early clinical results:
ABBV-295.
Developed by AbbVie, ABBV-295 is a long-acting amylin analogue being investigated for chronic weight management.
What makes it particularly interesting is not just its early effect on body weight.
Its unusually long half-life means researchers are exploring dosing schedules ranging from:
- once weekly
- every two weeks
- potentially once monthly
That could make ABBV-295 one of the more unusual entrants in the emerging amylin class. (AbbVie News Center)
What Is ABBV-295?
ABBV-295 is an investigational peptide designed to reproduce important aspects of the naturally occurring hormone amylin.
Amylin is normally released from pancreatic beta cells alongside insulin after eating.
It contributes to:
- satiety
- reduced food intake
- meal termination
- delayed gastric emptying
- post-meal metabolic regulation
ABBV-295 attempts to use this pathway without directly targeting GLP-1 or GIP.
AbbVie therefore describes it as a non-incretin, amylin-based approach to weight management. (AbbVie News Center)
Why Is the “Non-Incretin” Part Important?
Many of the leading metabolic medicines currently being developed rely heavily on incretin pathways.
These include:
GLP-1
and
GIP
ABBV-295 does something different.
It targets amylin biology instead.
That gives researchers another way to influence appetite without simply increasing GLP-1 signalling.
What Did the Phase 1 Study Investigate?
ABBV-295 was studied in a first-in-human clinical programme examining:
- safety
- tolerability
- pharmacokinetics
- appetite effects
- body-weight changes
The multiple-dose portion included adults with overweight or obesity.
Detailed 2026 results presented at the European Association for the Study of Diabetes included 60 participants in the relevant multiple-ascending-dose cohorts.
Forty-five received ABBV-295 and 15 received placebo. (AbbVie News Center)
How Was ABBV-295 Dosed?
Researchers tested several schedules.
These included:
- 4 mg once weekly
- 6 mg once weekly
- 14 mg once weekly
- 14 mg every other week
- 8 mg monthly
Treatment lasted approximately 12 to 13 weeks depending on the group. (AbbVie News Center)
The fact that monthly dosing was tested this early is particularly interesting.
How Much Weight Was Lost?
AbbVie reported dose-dependent reductions in body weight.
After approximately 12 weeks, the once-weekly groups showed average reductions ranging from about:
7.8% to 9.8%
The every-other-week group reached approximately:
9.7%
while the monthly regimen produced around:
7.9%
after approximately 13 weeks.
The placebo group lost only around:
0.3%. (AbbVie News Center)
These are early Phase 1 findings and should not be directly compared with much longer Phase 2 or Phase 3 trials of other metabolic therapies.
Why Is That Important?
Most Phase 1 trials are designed primarily to establish:
- safety
- pharmacokinetics
- dose tolerance
rather than prove long-term effectiveness.
Seeing sizeable changes in body weight during a relatively short first-in-human programme therefore provides a reason to investigate the compound further.
It does not prove what ABBV-295 would achieve after 52 or 68 weeks.
What Is ABBV-295’s Half-Life?
This may be the most distinctive aspect of the compound.
AbbVie reported a mean half-life of approximately:
10.7 to 12.3 days.
That is unusually long for a metabolic peptide. (AbbVie News Center)
Why Does Half-Life Matter?
Half-life describes roughly how long it takes the concentration of a drug in the body to fall by half.
A longer half-life can potentially allow:
- less-frequent injections
- steadier drug exposure
- simpler long-term treatment
- greater flexibility in maintenance therapy
ABBV-295’s pharmacokinetic profile is why AbbVie is investigating schedules beyond standard weekly dosing.
Could ABBV-295 Really Be Monthly?
Possibly.
Monthly administration was already included in the Phase 1 programme.
The 8 mg monthly group showed an average weight reduction of approximately 7.9% by week 13 in the reported cohort. (AbbVie News Center)
That does not establish that monthly dosing will ultimately become the commercial regimen.
Larger studies will need to determine:
- optimal dose
- effectiveness
- tolerability
- consistency between injections
- long-term safety
But the pharmacokinetics make the possibility credible.
What Were the Main Side Effects?
Gastrointestinal effects were reported, as expected for an appetite-regulating peptide.
These included:
- nausea
- diarrhoea
- reduced appetite
AbbVie reported that gastrointestinal adverse effects were predominantly mild.
Among participants reporting a gastrointestinal event, 92% had only mild events as their highest severity.
Nausea occurred in approximately 33.3% of ABBV-295 recipients versus 20% with placebo.
Diarrhoea occurred in approximately 20% versus none in the placebo group. (AbbVie News Center)
Were There Serious Safety Problems?
AbbVie reported no serious treatment-emergent adverse events in the detailed Phase 1 results.
Discontinuation because of gastrointestinal effects occurred in a small proportion of participants. (AbbVie News Center)
However, Phase 1 studies are small.
Uncommon adverse effects often cannot be identified until hundreds or thousands of people have been treated.
Has ABBV-295 Moved Into Phase 2?
Yes.
A Phase 2 study began in 2026 and is recruiting adults with obesity or overweight and weight-related conditions.
The study plans to enrol approximately 360 participants and compare several ABBV-295 dosing strategies with placebo.
The primary weight-related assessment is planned at week 32, with treatment continuing through a longer double-blind period. (DataLookout)
What Will Phase 2 Tell Us?
Phase 2 should provide much more useful information about:
- longer-term weight reduction
- optimal dose
- dosing frequency
- gastrointestinal tolerability
- treatment discontinuation
- metabolic changes
- whether weight loss continues beyond the first three months
This will be much more informative than the initial Phase 1 results alone.
How Is ABBV-295 Different From Cagrilintide?
Both are long-acting amylin analogues.
But their development strategies currently differ.
Cagrilintide has become strongly associated with:
CagriSema
combining amylin with semaglutide.
ABBV-295 is currently being developed primarily as a standalone amylin treatment.
ABBV-295 also has a particularly long half-life that could support less-frequent administration.
How Is ABBV-295 Different From Petrelintide?
Petrelintide is another long-acting amylin analogue and is considerably further along clinically.
Petrelintide has already entered Phase 3 development.
ABBV-295 remains earlier, currently moving through Phase 2.
However, ABBV-295’s potential for every-other-week or monthly administration could eventually become an important point of differentiation.
How Is ABBV-295 Different From Eloralintide?
Eloralintide is designed as a selective AMY1 receptor agonist.
ABBV-295 is described more broadly as a long-acting amylin analogue.
This means they represent two different approaches:
ABBV-295
→ reproduce long-lasting amylin biology.
Eloralintide
→ selectively target a particular amylin receptor subtype.
The eventual clinical data should help establish whether broad or selective receptor activity provides the better balance.
Could ABBV-295 Be Combined With GLP-1 Drugs?
Scientifically, this is certainly plausible.
Amylin and GLP-1 can produce complementary effects on appetite and satiety.
CagriSema has already demonstrated the rationale for combining the two pathways.
However, ABBV-295’s current clinical programme is important precisely because it is testing a non-incretin amylin approach.
Any combination involving ABBV-295 would require its own trials.
Could ABBV-295 Be Combined With Tirzepatide?
Again, the biology provides an obvious research question.
Tirzepatide provides:
GIP + GLP-1
ABBV-295 would add:
amylin
That resembles the broader strategy behind combinations such as eloralintide plus tirzepatide.
But there is a major difference between a biologically interesting idea and a clinically tested combination.
No assumption should be made that separately combining them would reproduce another amylin/incretin programme.
What About ABBV-295 + Retatrutide?
This would extend the same concept even further.
Retatrutide provides:
- GIP
- GLP-1
- glucagon
ABBV-295 would add:
- amylin signalling
The recent cagrilintide-retatrutide animal research shows why scientists are interested in this type of combination.
However, evidence involving cagrilintide cannot simply be transferred to ABBV-295.
ABBV-295 + retatrutide would require independent preclinical and human research.
Why Could Monthly Amylin Be Important?
Long-term metabolic treatment has a practical problem:
treatment burden.
Weekly injections may be manageable for many people.
But a drug requiring only one administration every:
- two weeks
- or four weeks
could potentially make long-term maintenance simpler.
This may become particularly important once obesity pharmacology moves from short-term weight reduction toward decades-long chronic treatment.
Could Less-Frequent Treatment Improve Adherence?
Potentially.
Fewer injections could reduce:
- treatment inconvenience
- missed doses
- injection fatigue
- storage and travel burden
But adherence is influenced by many factors beyond injection frequency.
These include:
- effectiveness
- adverse effects
- cost
- accessibility
- patient preference
Clinical trials would need to establish whether less frequent administration actually translates into better long-term persistence.
Could ABBV-295 Become a Maintenance Drug?
This is another interesting possibility.
Future obesity treatment may eventually separate into two phases:
active weight reduction
followed by
long-term maintenance.
A very long-acting amylin therapy could theoretically fit well into a maintenance model if it provides adequate appetite control with infrequent administration.
But that remains a future research question.
Does ABBV-295 Prove Amylin Can Work Without GLP-1?
The Phase 1 findings add to the evidence.
Participants receiving ABBV-295 experienced meaningful weight reductions despite the molecule being developed as a non-incretin therapy. (AbbVie News Center)
Petrelintide research points in the same general direction.
Together, these programmes suggest that amylin is capable of functioning as a substantial metabolic drug target in its own right.
Is This Why Pharmaceutical Companies Are Racing Into Amylin?
It is certainly part of the reason.
The current amylin pipeline now contains multiple competing approaches:
- cagrilintide
- petrelintide
- eloralintide
- ABBV-295
- AZD6234
- zenagamtide
Some are being developed alone.
Some are being combined with GLP-1.
Others are being paired with GIP/GLP-1 therapies.
This level of investment suggests that the industry increasingly sees amylin as one of the most important pathways beyond GLP-1.
Is ABBV-295 Approved?
No.
ABBV-295 remains an investigational compound.
It has not been approved by regulatory authorities for routine use.
Its safety and effectiveness still need to be demonstrated in larger and longer clinical trials. (AbbVie News Center)
What Are the Biggest Questions Now?
Phase 2 needs to answer several important questions.
Does the early weight reduction continue?
Three months is relatively short for modern obesity trials.
Can monthly dosing remain effective over a year?
Early pharmacokinetic results are encouraging, but long-term efficacy has not been established.
How tolerable is higher-dose treatment?
Larger populations will provide a clearer picture.
How does it affect body composition?
Researchers increasingly need to distinguish between fat loss and lean-mass loss.
Can it compete with established incretin therapies?
This will eventually require larger comparative studies.
Why Is ABBV-295 Worth Watching?
Because it combines three increasingly important themes in metabolic peptide research:
amylin biology
non-incretin weight management
and
extended dosing intervals.
Many current drugs compete by adding more receptors.
ABBV-295 represents another possibility:
use a different satiety pathway and make the molecule last much longer.
The Bottom Line
ABBV-295 is an investigational long-acting amylin analogue being developed by AbbVie for chronic weight management.
In detailed Phase 1 results presented in September 2026, weekly dosing produced average body-weight reductions of approximately 7.8% to 9.8% after 12 weeks.
An every-other-week regimen produced approximately 9.7%, while a monthly regimen produced around 7.9% after roughly 13 weeks. (AbbVie News Center)
Its mean half-life of approximately 11 to 12 days could potentially support dosing significantly less frequently than the once-weekly schedule common to many current metabolic peptides. (AbbVie News Center)
ABBV-295 has now advanced into Phase 2, where around 360 participants are expected to help establish whether those early results persist over longer treatment. (DataLookout)
The most interesting point may therefore not simply be how much weight ABBV-295 eventually produces.
It is whether long-acting amylin can become a major metabolic treatment without relying on GLP-1 at all — potentially with injections only every two weeks or once a month.
This article is for research and educational purposes only. ABBV-295 remains investigational and has not been approved for routine clinical use.